2O8M

Crystal structure of the S139A mutant of Hepatitis C Virus NS3/4A protease


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.194 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization

Prongay, A.J.Guo, Z.Yao, N.Pichardo, J.Fischmann, T.Strickland, C.Myers, J.Weber, P.C.Beyer, B.M.Ingram, R.Hong, Z.Prosise, W.W.Ramanathan, L.Taremi, S.S.Yarosh-Tomaine, T.Zhang, R.Senior, M.Yang, R.S.Malcolm, B.Arasappan, A.Bennett, F.Bogen, S.L.Chen, K.Jao, E.Liu, Y.T.Lovey, R.G.Saksena, A.K.Venkatraman, S.Girijavallabhan, V.Njoroge, F.G.Madison, V.

(2007) J.Med.Chem. 50: 2310-2318

  • DOI: 10.1021/jm060173k
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in c ...

    The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249-264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials.


    Organizational Affiliation

    Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. andrew.prongay@spcorp.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Protease
A, B
200Hepatitis C virus genotype 1a (isolate H)Mutation(s): 0 
Find proteins for P27958 (Hepatitis C virus genotype 1a (isolate H))
Go to UniProtKB:  P27958
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Protease
C, D
23Hepatitis C virus genotype 1a (isolate H)Mutation(s): 0 
Find proteins for P27958 (Hepatitis C virus genotype 1a (isolate H))
Go to UniProtKB:  P27958
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
NA
Query on NA

Download SDF File 
Download CCD File 
A, C
SODIUM ION
Na
FKNQFGJONOIPTF-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.194 
  • Space Group: H 3 2
Unit Cell:
Length (Å)Angle (°)
a = 224.640α = 90.00
b = 224.640β = 90.00
c = 75.360γ = 120.00
Software Package:
Software NamePurpose
BUSTERphasing
DENZOdata reduction
PDB_EXTRACTdata extraction
BUSTERrefinement
SCALEPACKdata scaling
CrystalCleardata collection

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2007-10-09
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance
  • Version 1.2: 2017-10-18
    Type: Refinement description